MED54 - Influenza Vaccine for the 2020 - 2021 Flu Season

The Commonwealth of Massachusetts, through the Operational Services Division (OSD), is seeking bids for the procurement of influenza vaccines for the 2020-2021 flu season under the MED54 contract. The contract will be the primary statewide vehicle for Executive Agencies, as well as cities, towns, public schools, and state colleges to acquire injectable inactivated subviron, nasal spray live attenuated, and recombinant HA influenza vaccines. The estimated total procurement value is $1 million. Bids are due by January 7, 2020, and the contract is expected to start on February 1, 2020 for an initial 1-year term. Pricing will account for 80% of the total evaluation score, with additional points awarded for supplier diversity plan commitments and prompt payment discounts. The contract will be subject to a 1% administrative fee payable to OSD.

The MED54 contract opportunity includes a Supplier Diversity Program (SDP) requirement, which mandates that bidders commit to a specific annual percentage of contract sales to be spent with certified SDP partners. Lists of certified SDP partners are available on the Massachusetts Supplier Diversity Office website, and OSD offers training on SDP plan compliance. The apparent successful bidders for the MED54 contract are GlaxoSmithKline LLC, Henry Schein Inc., McKesson Medical-Surgical Minnesota Supply Inc., and Sanofi Pasteur Inc. The state may choose not to purchase doses on this contract, but other eligible government entities will be able to do so.